Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Top-line data expected Q3 of 2019 Also reports recent results from clinician survey on radiocontrast agent selection and use SAN…
Pharmaceuticals, Biotechnology and Life Sciences
Top-line data expected Q3 of 2019 Also reports recent results from clinician survey on radiocontrast agent selection and use SAN…
DUBLIN–(BUSINESS WIRE)–The “Dermatological Therapeutics Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…
Apristor® (onapristone extended release), a full progesterone receptor antagonist, is being studied in patients with rare gynecological cancers who are…
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it will present clinical and health economic outcomes data from its…
– Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease CAMBRIDGE, Mass. &…
Financing to fund quarterly expenses related to the ATHENA first-line maintenance clinical trial in ovarian cancer, beginning in Q2 2019…
Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients…
– Selected 150 mg for the dose expansion trial for AB928, the Company’s dual A2a/A2b receptor antagonist, in combination with…
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that William…
– Leverages Strata Oncology’s Proprietary Biomarker Technology to Stratify Patients – HAYWARD, Calif. and ANN ARBOR, Mich.–(BUSINESS WIRE)–Arcus Biosciences, Inc.…